Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 12, 2019Pharmaceutical Statistics

TITE‐BOIN‐ET: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding based on both efficacy and toxicity outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

KTKentaro TakedaCenter for Global DevelopmentSMSatoshi MoritaKyoto UniversityMTMasataka TaguriNihon University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Takeda et al. (2019) studied this question.

synapsesocial.com/papers/6a625f21b8617574e1f56eb5https://doi.org/10.1002/pst.1995
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?2009 · 101 citations
  2. 2Toxicities of Immunotherapy for the Practitioner2015 · 659 citations
  3. 3Time-to-Event Model-Assisted Designs to Accelerate Phase I Clinical Trials2018 · 4 citations